Crystalys Therapeutics has dosed the first patients in a Phase II trial evaluating a treatment for difficult-to-treat gout. The trial will evaluate dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout, particularly in patients with limited treatment… Read More
Biopharmaceutical company Crystalys Therapeutics has launched with a $205 million Series A financing round, aiming to address the significant unmet medical needs of people living with gout. The financing round was co-led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of… Read More
Atom Bioscience has revealed positive results from its China Phase IIa clinical trial of ABP-671, its URAT1 inhibitor for chronic gout. The randomised, double-blind, placebo-controlled trial enrolled 54 patients with gout or across six cohorts, with seven randomised to ABP-671 and two to placebo per cohort. … Read More
